1Atlas SA.The renin-angiotensin aldosterone system:pathophysiological role and pharmacologic inhibition.Journal of managed care pharmacy.JMCP,2007,13 (8 Suppl B):9-20.
2Suganuma T,Ino K,Shibata K,et al.Functional expression of the angiotensin Ⅱ type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion,angiogenesis,and peritoneal dissemination.Clinical cancer research,2005,11 (7):2686-2694.
3Escobar E,Rodriguez-Reyna TS,Arrieta O,et al.Angiotensin Ⅱ,cell proliferation and angiogenesis regulator:biologic and therapeutic implications in cancer.Current vascular pharmacology,2004,2(4):385-399.
4Suzuki Y,Ruiz-Ortega M,Lorenzo O,et al.Inflammation and angiotensin Ⅱ.The international journal of biochemistry & cell biology,2003,35(6):881-900.
5Taniguchi T,Kurita A,Kobayashi K,et al.Dose-and time-related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats.Journal of anesthesia,2008,22(3):221-228.
6Egami K,Murohara T,Shimada T,et al.Role of host angiotensin Ⅱ type 1 receptor in tumor angiogenesis and growth.Journal of Clinical Investigation,2003,112(1):67-75.
7Akhavan MM,Karimi M,Ghodrati M,et al.AT1 receptors activation enhances the expression of MMP-2,MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells.Pakistan journal of biological sciences:PJBS,2011,14(17):821-830.
8Tanaka N,Miyajima A,Kosaka T,et al.Acquired platinum resistance enhances tumour angiogenesis through angiotensin Ⅱ type 1 receptor in bladder cancer.British journal of cancer,2011,105(9):1331-1337.
4LEVER A F, HOLE D J, GILLIS C R, et al. Do inhibitors of angiotensin- I -converting enzyme protect against risk of cancer[ J ]. Lancet, 1998, 352(9123) :179-184.
5KOSUGI M, MIYAJIMA A, KIKUCHI E, et al. Angiotensin Ⅱ type I receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer[ J]. Clin Cancer Res, 2006, 12(9) :2888-2893.
6SUGANUMA T, INO K, SHIBATA K, et al. Functional expression of the angiotensin Ⅱ type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination [ J ]. Clin Cancer Res, 2005, 11 (7) :2686-2694.
8ROUSSEAU S,HOULE F, LANDRY J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells [ J ]. Oncogene, 1997, 15(18):2169.
9Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma [ J ]. N Engl J Med,1991,324 (1) :79-81.
10Takeda H, Kondo S. Differences between squamous cell carinoma and keratoacanthoma in anglotensin type-1 receptor expression[J]. Am J Pathol, 2001, 158(5) :1633-1637.
